Special Issue "Pharmaceutical Technology and Formulations for the Treatment of Eye Diseases"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 10 February 2024 | Viewed by 147

Special Issue Editors

Department of Ophthalmology, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, 30 Voie Romaine, 06000 Nice, France
Interests: medical and surgical retina; AMD; uveitis
Dr. Luc Demange
E-Mail Website
Guest Editor
CiTCoM, UMR 8038 CNRS, Faculté de Pharmacie, Université de Paris Cité, 4, Avenue de l’Observatoire, 75270 Paris, France
Interests: age-related maculopathy; dry age-related macular degeneration; wet age-related macular degeneration; eye’s disease

Special Issue Information

Dear Colleagues,

The eye is considered the second most complex organ in the body after the brain. This complexity results from a variety of different anatomical structures and many physiologically independent functions.

Ophthalmic formulations are specialized drug compositions, specifically designed and constructed for the delivery of drugs to the eye. Ocular drug delivery suffers from many barrier effects such as drug loss from the ocular surface, small penetration through the corneal layers, and rapid systemic absorption. For posterior eye diseases, conventional drug delivery systems, such as eye drops, suspensions and ointments are not suitable for attaining optimal treatment results. Other routes for ocular drug delivery are necessary such as intravitreal, subretinal or suprachoroidal routes. The challenge is thus to design a drug with a high therapeutic efficacy which can be administered with an optimal concentration to the target region of the eye.

The aim of this Special Issue is to highlight the newest developments in pharmaceutical ophthalmic formulations, showcasing their progress in improving bioavailability and drug duration into the eye, as well as enhancing delivery to the targeted compartment of the eye.

Prof. Dr. Stephanie Baillif
Dr. Luc Demange
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • delivery route
  • formulation
  • durability
  • bioavailability
  • controlled ocular drug delivery
  • ocular inserts
  • implants
  • gene therapy

Published Papers

This special issue is now open for submission.
Back to TopTop